Eric Ostertag Biography and Net Worth

Dr. Ostertag directed Poseida’s spin out from Transposagen in February 2015 and has served as our Chief Executive Officer and as a member of our board of directors since May 2015. From October 2003 to July 2015, Dr. Ostertag founded and served as the Chief Executive Officer and President of Transposagen Biopharmaceuticals, Inc., a biotechnology company that commercializes early gene editing technology in the research reagent space. Dr. Ostertag previously co-founded and served as Chief Executive Officer and President of Vindico NanoBioTechnology, Inc., a biotechnology company engaged in the discovery, development, and commercialization of human therapeutics that are based on a nanometer-scale particulate technology. Dr. Ostertag also co-founded and served as Executive Vice President of PhenoTech, Inc., a biotechnology company engaged in the discovery, development, and commercialization of reagents for diagnostic use in blood banks. Dr. Ostertag received both his Ph.D. in molecular biology and his M.D. from the University of Pennsylvania School of Medicine and his B.S. in genetics from the University of Wisconsin-Madison.

What is Eric Ostertag's net worth?: The estimated net worth of Eric Ostertag is at least $2.28 million as of August 8th, 2022. Dr. Ostertag owns 838,824 shares of Poseida Therapeutics stock worth more than $2,281,601 as of November 21st. This net worth approximation does not reflect any other assets that Dr. Ostertag may own. Learn More about Eric Ostertag's net worth.
How do I contact Eric Ostertag?: The corporate mailing address for Dr. Ostertag and other Poseida Therapeutics executives is 9390 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. Poseida Therapeutics can also be reached via phone at 858-779-3100 and via email at [email protected]. Learn More on Eric Ostertag's contact information.
Has Eric Ostertag been buying or selling shares of Poseida Therapeutics?: Eric Ostertag has not been actively trading shares of Poseida Therapeutics over the course of the past ninety days. Most recently, on Monday, August 8th, Eric Ostertag bought 142,857 shares of Poseida Therapeutics stock. The stock was acquired at an average cost of $3.50 per share, with a total value of $499,999.50. Following the completion of the transaction, the chairman now directly owns 838,824 shares of the company's stock, valued at $2,935,884. Learn More on Eric Ostertag's trading history.
Who are Poseida Therapeutics' active insiders?: Poseida Therapeutics' insider roster includes Kerry Ingalls (COO), Eric Ostertag (CEO), and Matthew Spear (Insider). Learn More on Poseida Therapeutics' active insiders.

Eric Ostertag Insider Trading History at Poseida Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/8/2022	Buy	142,857	$3.50	$499,999.50	838,824
8/3/2022	Sell	160,696	$3.69	$592,968.24	695,967
11/8/2021	Sell	18,924	$7.09	$134,171.16
10/1/2021	Sell	20,029	$7.02	$140,603.58
9/20/2021	Sell	20,000	$8.00	$160,000.00
9/14/2021	Sell	20,000	$8.14	$162,800.00
7/1/2021	Sell	20,563	$9.77	$200,900.51
6/1/2021	Sell	41,194	$8.61	$354,680.34	542,985
5/3/2021	Sell	18,326	$9.01	$165,117.26	542,985
4/5/2021	Sell	57,819	$9.66	$558,531.54	542,985
4/1/2021	Sell	57,181	$9.55	$546,078.55	542,985
2/16/2021	Sell	133,149	$10.00	$1,331,490.00	431,590
2/10/2021	Sell	12,389	$10.00	$123,890.00	431,590
1/21/2021	Sell	4,462	$10.00	$44,620.00	364,056

Eric Ostertag Buying and Selling Activity at Poseida Therapeutics

Poseida Therapeutics Company Overview

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.

Today's Range

Now: $2.72

$2.64

$2.82

50 Day Range

MA: $2.80

$2.37

$3.71

2 Week Range

Now: $2.72

$1.87

$4.27

Volume

438,812 shs

Average Volume

557,441 shs

Market Capitalization

$265.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.54

Top "Sleeping Giant" Crypto In The Market Now

From Crypto 101 Media | Ad

Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future.

Click here to discover our #1 crypto pick before it's too late